Hand Foot Syndrome Market Report 2025

The hand foot syndrome market size has grown strongly in recent years. It will grow from $0.48 billion in 2024 to $0.52 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to the rising prevalence of chronic diseases, an increase in global cancer diagnoses, a growing emphasis on patient-centered cancer care, higher government initiatives and healthcare funding, and a growing focus by pharmaceutical companies on rare and orphan diseases.

The hand foot syndrome market size is expected to see strong growth in the next few years. It will grow to $0.67 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth during the forecast period can be attributed to the increasing emphasis on palliative and symptom management care, growth in oncology biopharmaceuticals, a rise in clinical trials for HFS treatments, increasing demand for oral and at-home treatments, and a global increase in health insurance coverage. Key trends expected in this period include the integration of virtual reality (VR) for symptom management, advancements in wearable health devices, the use of CRISPR technology for gene editing and personalized treatments, the development of AI-powered predictive tools, and the application of 3D imaging for better understanding of skin conditions.

The rising incidence of cancer is expected to drive the growth of the hand-foot syndrome market. Cancer is a condition characterized by uncontrolled cell growth that spreads to other parts of the body. The increasing number of cancer cases is influenced by factors such as aging populations, lifestyle changes, environmental exposures, and advancements in detection methods. As cancer cases rise, chemotherapy usage also increases, leading to a higher prevalence of hand-foot syndrome, which is a common side effect of chemotherapy treatments. For example, in August 2024, Macmillan Cancer Support, a UK-based charity, reported that over 3 million people in the UK were living with cancer. This figure is projected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. As a result, the growing number of cancer cases will contribute to the expansion of the hand-foot syndrome market.

Companies operating in the hand-foot syndrome market are focusing on technological innovations such as image-guided radiotherapy (IGRT) to improve the precision and effectiveness of treatments, enhance patient outcomes, and minimize damage to healthy tissues. IGRT uses advanced imaging techniques to ensure accurate tumor targeting during radiation therapy, allowing real-time tracking and adjustment of the tumor's position. For instance, in May 2022, Elekta AB, a Sweden-based medical technology company, introduced the Elekta Esprit, a next-generation radiosurgery system that improves the capabilities of stereotactic radiosurgery. The Elekta Esprit integrates various innovations into a single platform, offering superior visualization and remote accessibility for treatment teams. It also supports flexible workflows, accommodating single-session, fractionated, adaptive, or staged protocols, all designed to improve efficiency and ease of use in clinical environments.

In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.5 billion. This acquisition aims to strengthen AstraZeneca's oncology portfolio with advanced radiopharmaceuticals, such as FPI-2265, enhance its research and development and manufacturing capabilities, and accelerate the transition to targeted cancer therapies while expanding its presence in Canada. Fusion Pharmaceuticals Inc. is a biotechnology company based in Canada that specializes in developing next-generation radiopharmaceuticals as precision medicines for cancer treatment.

Major players in the hand foot syndrome market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Fresenius Kabi AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB Pharma SA, and Eisai Co. Ltd.

Asia-Pacific was the largest region in the hand food syndrome market in 2024. The regions covered in hand foot syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hand foot syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hand foot syndrome, also known as palmar-plantar erythrodysesthesia, is a condition triggered by chemotherapy or certain medications. It leads to redness, swelling, pain, and peeling on the palms of the hands and the soles of the feet. In more severe cases, blisters and ulcerations may develop, impacting daily activities.

The primary treatments for hand foot syndrome include both systemic and topical options. Systemic treatments involve medications that work throughout the body to relieve symptoms and prevent complications. These treatments are utilized in various fields such as oncology, dermatology, and others, and are typically administered in hospitals, clinics, and homecare settings.

The hand foot syndrome market research report is one of a series of new reports that provides hand foot syndrome market statistics, including the hand foot syndrome industry's global market size, regional shares, competitors with a hand foot syndrome market share, detailed hand foot syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the hand foot syndrome industry. This hand foot syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hand foot syndrome market consists of revenues earned by entities providing services such as treatments, therapies, and supportive care services for managing symptoms and complications of the condition. The market value includes the value of related goods sold by the service provider or included within the service offering. The hand foot syndrome market also includes sales of pharmaceutical drugs, topical treatments, and medical devices used to alleviate symptoms and manage the condition. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.